Dna Testing Centers (DNAT) Return on Equity ROE from the fourth quarter 2018 to fourth quarter 2017 and annually, average high and low, overall ranking from Dec 31 2018 to Mar 31 2017 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Dna Testing Centers Corp  (DNAT)

Dna Testing Centers's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Dna Testing Centers in the fourth quarter 2018?
Due to the lack of equity, it was not possible to calculate Dna Testing Centers Corp's return on equity (ROE) in its fourth quarter 2018

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2018)
IV. Quarter		 (Dec 31 2017)
IV. Quarter		 (Sep 30 2017)
III. Quarter		 (Jun 30 2017)
II. Quarter		 (Mar 31 2017)
I. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions 0 0 0 0 0
Return On Equity (TTM) - - - - -
DNAT's Total Ranking # # # # #
Equity (TTM) in Millions 0 0 0 0 0
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to DNAT Management Effectiveness >> DNAT's 5 Years Annual ROE >> Compare DNAT ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





DNAT Annual Return On Equity (Dec 31 2018)
2018		 (Dec 31 2017)
2017		 (Dec 31 2016)
2016		 (Dec 31 2015)
2015
Total Equity in Millions 0 0 0 0 0
Y / Y Equity Change - - - - -
Net Income in Millions 0 0 0 0 0
Y / Y Net Income Change - - - - -
Return On Equity - - - - -

Back to DNAT Management Effectiveness >> DNAT's 5 Years Annual ROE >> Compare DNAT ROE to its Competitors




More Return On Equity Ratios
In Vitro & In Vivo Diagnostic Substances Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
DNAT's' Return on Equity at Yahoo Finance
DNAT's Roe Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for DNAT's Competitors
Subscribers only: Roe for Dna Testing Centers's Suppliers
Subscribers only: Return On Equity for DNAT's Customers




Companies with similar Return On Equity at Dec 31 2018, within Healthcare Sector ROE
Waters Corporation  31.53 %
Corcept Therapeutics Inc  30.34 %
Tivity Health Inc   29.71 %
Lifevantage Corp  29.37 %
Abiomed Inc   29.03 %
Supernus Pharmaceuticals inc   27.45 %
Ionis Pharmaceuticals Inc   27.34 %
Radnet Inc   27.10 %
Amedisys Inc  25.47 %
Alpha Pro Tech Ltd   25.29 %
Eli Lilly And Company  25.22 %
Encompass Health Corporation  25.13 %
Gilead Sciences Inc   25.12 %
Agilent Technologies inc   24.88 %
Regenxbio Inc   24.68 %
Psychemedics Corporation  24.55 %
Johnson and Johnson  24.42 %
Ligand Pharmaceuticals Incorporated  24.28 %
Icon Plc  23.82 %
Varian Medical Systems Inc   23.53 %
Enanta Pharmaceuticals Inc  23.29 %
Biospecifics Technologies Corp  23.01 %
U S Physical Therapy Inc  22.95 %
Carlisle Companies Incorporated  22.85 %
United Therapeutics Corporation  22.63 %
Illumina Inc   22.59 %
Edwards Lifesciences Corporation  22.37 %
Masimo Corp  22.29 %
Resmed Inc   22.28 %
Bruker Corporation  21.90 %

Date modified: 2026-08-30T10:51:15+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.